At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,162 enrolled
Drug / intervention
Vilazodone +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo- and Active-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder
In Brief
A Phase 4 clinical trial evaluating Vilazodone, Placebo to citalopram, and 2 other interventions for Major Depressive Disorder. Completed, enrolled 1,162 participants across 54 sites.
Detailed Summary
The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartDec 2011
Primary CompletionJun 2013
TodayJul 2026
First PostedNov 17, 2011
Enrollment StartDec 1, 2011
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.6 years ago
Interventions
Vilazodonedrug
Vilazodone was supplied as film-coated tablets.
Placebo to citalopramdrug
Placebo to citalopram was supplied as a capsule.
Placebo to vilazodonedrug
Placebo to vilazodone was supplied as film-coated tablets.
Citalopramdrug
Citalopram was supplied as encapsulated tablets.